Abstract

The invention relates to use of specific peptides derived from the cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. The invention further relates to compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Original languageAmerican English
Patent numberWO2013140393
IPCC07K 14/ 705 A I
Priority date21/03/12
StatePublished - 26 Sep 2013

Fingerprint

Dive into the research topics of 'PEPTIDES DERIVED FROM THE D1 - DOMAIN OF NKP46'. Together they form a unique fingerprint.

Cite this